WINTON GROUP Ltd Has $1.30 Million Holdings in Progyny, Inc. (NASDAQ:PGNY)

WINTON GROUP Ltd lifted its position in Progyny, Inc. (NASDAQ:PGNY) by 62.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,515 shares of the company’s stock after buying an additional 29,124 shares during the quarter. WINTON GROUP Ltd owned about 0.09% of Progyny worth $1,303,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Progyny by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company’s stock valued at $149,939,000 after acquiring an additional 48,271 shares during the period. Pacer Advisors Inc. grew its holdings in Progyny by 47.5% during the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock worth $63,414,000 after purchasing an additional 1,183,558 shares during the period. State Street Corp increased its position in Progyny by 4.5% during the third quarter. State Street Corp now owns 3,113,654 shares of the company’s stock worth $52,185,000 after buying an additional 134,861 shares during the last quarter. Invenomic Capital Management LP bought a new stake in Progyny in the third quarter valued at approximately $29,509,000. Finally, River Road Asset Management LLC acquired a new stake in shares of Progyny in the fourth quarter valued at approximately $25,529,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Up 2.2 %

Shares of Progyny stock opened at $22.31 on Friday. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $38.98. The company has a 50-day simple moving average of $22.05 and a two-hundred day simple moving average of $18.58. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 38.47, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Finally, Canaccord Genuity Group raised their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, February 28th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $24.82.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.